Glialign
London
About Glialign
Glialign is developing a novel cell therapy for peripheral nerve repair ’ for which current therapies are only successful in less than half of the cases and often can require grafting of a nerve from another part of the body.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Funding stage: Seed
- Last round: Seed (May 2018)
- Website: glialign.com
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/glialign-2650533 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.